Royalty Pharma to Discuss Strategy at TD Cowen Health Care Conference

Event summary

  • Royalty Pharma to participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026, at 1:10 p.m. ET.
  • Webcast will be accessible from Royalty Pharma’s “Events” page and archived for at least 30 days.
  • Royalty Pharma manages royalties on over 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, and Roche’s Evrysdi.
  • Company funds innovation through direct partnerships and acquisitions of existing royalties.

The big picture

Royalty Pharma’s participation in TD Cowen’s Health Care Conference underscores its role as a key player in biopharmaceutical royalty management. The company’s strategy of funding innovation through royalties on leading therapies positions it uniquely in the industry. As the biopharmaceutical landscape evolves, Royalty Pharma’s ability to navigate market dynamics and maintain its portfolio’s performance will be critical.

What we're watching

Portfolio Performance
How the performance of key royalties like Vertex’s Trikafta and GSK’s Trelegy will impact Royalty Pharma’s revenue streams.
Strategic Partnerships
Whether Royalty Pharma can sustain its growth through new partnerships and acquisitions in the biopharmaceutical sector.
Market Dynamics
The pace at which Royalty Pharma can expand its portfolio amid increasing competition in the royalty management space.